Jazz Pharmaceuticals plc – Receives Consensus Rating of “Buy” from Brokerages (NASDAQ:JAZZ)
Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) have been given an average rating of “Buy” by the nineteen ratings firms that are presently covering the stock, Analyst Ratings Net reports. Five analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $171.50.
In other Jazz Pharmaceuticals plc – news, EVP Fintan Keegan unloaded 3,750 shares of the company’s stock on the open market in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $150.00, for a total value of $562,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on JAZZ shares. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Friday. They now have a $157.00 price target on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 17th. They set an “outperform” rating and a $179.00 price target on the stock. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) opened at 153.50 on Tuesday. Jazz Pharmaceuticals plc – has a 1-year low of $65.37 and a 1-year high of $176.60. The stock’s 50-day moving average is $139.5 and its 200-day moving average is $141.2. The company has a market cap of $9.117 billion and a price-to-earnings ratio of 116.73.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings data on Thursday, May 8th. The company reported $1.61 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the prior year, the company posted $1.37 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.07 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.